Benitec Biopharma Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2021, the company’s first fiscal quarter of fiscal 2022. Financial statements are unaudited and reported in U.S. dollars. Benitec is a development-stage biotechnology company developing genetic medicines using its DNA-directed RNA interference (ddRNAi) platform.
Financial performance and position
| Metric | Quarter ended September 30, 2021 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $55,000 |
| Research and development expense | $2.78 million | $0.77 million |
| General and administrative expense | $2.04 million | $1.84 million |
| Total operating expenses | $4.82 million | $2.75 million |
| Net loss | $5.05 million | $2.72 million |
| Net loss per share, basic and diluted | $0.62 | $2.45 |
| Net cash used in operations | $4.28 million | $2.36 million |
Cash and cash equivalents were $15.73 million at September 30, down from $19.77 million at June 30, 2021. Total assets were $17.84 million and stockholders’ equity was $15.48 million. Current liabilities were $1.60 million; the company reported no borrowings and no credit facility. Operating lease liabilities totaled $954,000, including $194,000 current. The filing reports no product-sale revenue and no material off-balance-sheet arrangements.
The company recorded a $240,000 foreign-currency transaction loss and an $18,000 unrealized investment gain. Other comprehensive income included a $239,000 foreign-currency translation gain. The lower loss per share versus the prior-year quarter reflects a substantially larger weighted-average share count (8.17 million versus 1.11 million), not an improvement in net loss.
Changes versus the prior-year quarter
- Net loss increased by $2.33 million, primarily as research and development spending rose by about $2.01 million. Management attributed the increase mainly to the BB-301 regulatory toxicology study and related development and manufacturing work.
- Cash used in operations increased by $1.92 million. Cash declined by $4.04 million during the quarter, partly offset by $236,000 from exchange-rate movements.
- Revenue fell to zero from $55,000, reflecting lower licensing and royalty revenue. Royalties and license fees expense also fell to zero from $134,000.
- General and administrative expense rose modestly, which management attributed to increases in insurance, consulting, legal and accounting costs.
Outlook, development programs and risks
- BB-301, the lead program for oculopharyngeal muscular dystrophy (OPMD), was undergoing CTA- and IND-enabling work. The company planned to initiate a first-in-human Phase 1b/2a study in 2022, subject to required development and regulatory steps; no product is approved for sale.
- The BB-301 Beagle pilot dosing study was completed without incident. Interim analyses covered 16 of 24 animals and were described by the company as showing improved pharyngeal-tissue transduction with its revised administration and analytical methods. Analyses were ongoing; these are nonclinical findings, not human clinical results.
- Management said the company had at least 12 months of funding from the report date, based on cash-flow forecasts. It expects continuing operating losses and says future funding needs depend on development costs, regulatory outcomes and potential collaboration or licensing arrangements. There is no assurance additional revenue or financing will be obtained.
- BB-103, for chronic hepatitis B, had shown nonclinical activity; the company was seeking strategic partners to advance it through IND-enabling studies.
- COVID-19 had delayed aspects of BB-301 development and created supply-chain and operational risks. The company cited potential further delays, clinical and regulatory uncertainty, reliance on collaborators and vendors, intellectual-property risks, competition, and the need for additional financing.
- The company extended its office lease through June 2025. It reported no material pending or threatened litigation and no material changes to the risk factors in its latest Form 10-K.
Key facts for investors to verify
- Whether BB-301’s ongoing GLP toxicology and biodistribution work supports the planned clinical timeline, dose selection and regulatory filings.
- Whether the stated cash runway remains adequate as development spending increases; verify subsequent cash use and any financing or partnership activity.
- How interim nonclinical pilot-study results compare with the final analysis of all 24 animals and whether regulators accept the supporting data.
- Whether the company secures partners or licensing revenue for BB-103 or other programs, given the absence of product revenue and continued operating losses.
- The effect of the lease extension and other contractual commitments on future liquidity, and the sensitivity of results and cash to foreign-exchange movements.